| Lyme Disease |
1 |
1 |
| COVID-19 |
0 |
1 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.65 |
| Chronic Disease |
0 |
0.58 |
| Healthcare and Medical Technology |
0 |
0.38 |
| HIV Infection |
0 |
0.34 |
| Chronic Fatigue Syndrome |
0 |
0.23 |
| Clinical Research |
0 |
0.19 |
| New York |
0 |
0.16 |
| Tick-Borne Diseases |
0 |
0.16 |
| Viral Infection |
0 |
0.16 |
| Cerebrovascular Accident |
0 |
0.15 |
| Multiple Sclerosis |
0 |
0.14 |
| California |
0 |
0.13 |
| Child |
0 |
0.13 |
| Medical Innovations |
0 |
0.13 |
| Pathogenesis |
0 |
0.13 |
| Tissue |
0 |
0.13 |
| Biologic Therapy |
0 |
0.11 |
| Ebola Virus |
0 |
0.11 |
| HIV Pathogenesis |
0 |
0.11 |
| Microbiome |
0 |
0.11 |
| Biomarker |
0 |
0.1 |
| Epidemiology |
0 |
0.1 |
| Antibiotics |
0 |
0.08 |
| Complementary and Alternative Medicine |
0 |
0.08 |
| Brain |
0 |
0.07 |
| Fatigue |
0 |
0.07 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.07 |
| Pneumonia |
0 |
0.07 |